Double-blind trial of tiapride versus placebo in patients with sub perennial idiopathic headache

25 patients with sub-perennial idiopathic headache were given tiapride or a placebo in a double-blind controlled trial, over thirteen weeks. Tiapride was given orally in a dosage of 300 mg per day. Blood was drawn in 10 patients and 10 healthy controls for blood prolactin determination. No significant side-effects were recorded during the trial. Statistical analysis of the results is reported. Tiapride proved effective in reducing the frequency of headache (in 65% of patients), with an improvement rate which was statistically significant in comparison to the placebo. The drug seems to improve the headache index itself, although the difference was not statistically significant; however, the number of patients was small.